HDM201

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Malignant Solid TumorAdvanced Soft-Tissue Sarcoma

20 competitors in Malignant Solid Tumor

#DrugCompanyPhaseTrials

1

Kisqali

Novartis

Phase 2

12

Cabometyx

Bristol-Myers Squibb

Phase 2

13

Alecensa

Roche

Phase 2

14

Stivarga

Bayer

Phase 2

15

Mekinist

Novartis

Phase 2

16

Tafinlar

Novartis

Phase 2

17

Ayvakit

BBlueprint Medicines

Phase 2

18

Keytruda

Merck & Co.

Phase 1

39

Paraplatin

AAvyxa

Phase 1

210

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

2Show 10 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Newly Diagnosed1 trial

HDM201 Added to CT in R/R or Newly Diagnosed AML

Withdrawn·Novartis·Phase 1/2·NCT03760445

Myelodysplastic Syndrome1 trial

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Terminated·Novartis·Phase 1·NCT03940352·52 enrolled

Metastatic Colorectal Cancer1 trial

Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type

Completed·CCentre Leon Berard·Phase 1·NCT03714958·12 enrolled

Relapsed/Refractory AML1 trial

HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.

Terminated·IInsel Gruppe AG, University Hospital Bern·Phase 1·NCT04496999·2 enrolled

Liposarcoma1 trial

Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma

Completed·Novartis·Phase 1·NCT02343172·74 enrolled

4 more indications

Advanced1 trial

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

Completed·Novartis·Phase 1·NCT02143635·208 enrolled

Malignant Solid Tumor1 trial

MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors.

Recruiting·CCentre Leon Berard·Phase 2·NCT04116541·455 enrolled

Advanced Soft-tissue Sarcoma1 trial

A Multicenter, Phase I/II Study Evaluating the Clinical Impact of HDM201 + Pazopanib in Patients With P53 Wild-type Advanced/ Metastatic Soft Tissue Sarcomas (AMPHISARC)

Active, not recruiting·CCentre Leon Berard·Preclinical·NCT05180695·47 enrolled

Unspecified1 trial

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Completed·Novartis·Phase 1·NCT02890069·298 enrolled

Details

Drug Info

Related News